These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 19347015)

  • 1. Endocrine and liver interaction: the role of endocrine pathways in NASH.
    Loria P; Carulli L; Bertolotti M; Lonardo A
    Nat Rev Gastroenterol Hepatol; 2009 Apr; 6(4):236-47. PubMed ID: 19347015
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Role of the endocrine system in the pathogenesis of non-alcoholic fatty liver disease].
    Hagymási K; Reismann P; Rácz K; Tulassay Z
    Orv Hetil; 2009 Nov; 150(48):2173-81. PubMed ID: 19923096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic steatohepatitis and nonalcoholic Fatty liver disease in young women with polycystic ovary syndrome.
    Setji TL; Holland ND; Sanders LL; Pereira KC; Diehl AM; Brown AJ
    J Clin Endocrinol Metab; 2006 May; 91(5):1741-7. PubMed ID: 16492691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonalcoholic steatohepatitis.
    Brunt EM
    Semin Liver Dis; 2004 Feb; 24(1):3-20. PubMed ID: 15085483
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pathophysiology of NASH in endocrine diseases.
    Gariani K; Jornayvaz FR
    Endocr Connect; 2021 Feb; 10(2):R52-R65. PubMed ID: 33449917
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome.
    Tan S; Bechmann LP; Benson S; Dietz T; Eichner S; Hahn S; Janssen OE; Lahner H; Gerken G; Mann K; Canbay A
    J Clin Endocrinol Metab; 2010 Jan; 95(1):343-8. PubMed ID: 19906783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease.
    Yalamanchili K; Saadeh S; Klintmalm GB; Jennings LW; Davis GL
    Liver Transpl; 2010 Apr; 16(4):431-9. PubMed ID: 20373454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. NASH in Nondiabetic Endocrine Disorders.
    Wang T; Yang W; Karakas S; Sarkar S
    Metab Syndr Relat Disord; 2018 Sep; 16(7):315-320. PubMed ID: 29873585
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etiopathogenesis of nonalcoholic steatohepatitis.
    Chitturi S; Farrell GC
    Semin Liver Dis; 2001; 21(1):27-41. PubMed ID: 11296694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings.
    Brown AJ; Tendler DA; McMurray RG; Setji TL
    Endocr Pract; 2005; 11(5):319-24. PubMed ID: 16191492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatic manifestations of women with polycystic ovary syndrome.
    Chen MJ; Ho HN
    Best Pract Res Clin Obstet Gynaecol; 2016 Nov; 37():119-128. PubMed ID: 27107966
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endocrine disorders associated with obesity.
    Park HK; Ahima RS
    Best Pract Res Clin Obstet Gynaecol; 2023 Aug; 90():102394. PubMed ID: 37523934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prevalence of nonalcoholic fatty liver disease and metabolic syndrome in obese children].
    Shi HB; Fu JF; Liang L; Wang CL; Zhu JF; Zhou F; Zhao ZY
    Zhonghua Er Ke Za Zhi; 2009 Feb; 47(2):114-8. PubMed ID: 19573457
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: from steatosis to cirrhosis.
    Farrell GC; Larter CZ
    Hepatology; 2006 Feb; 43(2 Suppl 1):S99-S112. PubMed ID: 16447287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [NASH in children].
    Ida S; Yoshimura N
    Nihon Rinsho; 2006 Jun; 64(6):1168-72. PubMed ID: 16768127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic effects of reduced growth hormone action in fatty liver disease.
    Rufinatscha K; Ress C; Folie S; Haas S; Salzmann K; Moser P; Dobner J; Weiss G; Iruzubieta P; Arias-Loste MT; Crespo J; Tilg H; Kaser S
    Hepatol Int; 2018 Sep; 12(5):474-481. PubMed ID: 30206761
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
    Baranova A; Tran TP; Birerdinc A; Younossi ZM
    Aliment Pharmacol Ther; 2011 Apr; 33(7):801-14. PubMed ID: 21251033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A fresh look at NASH pathogenesis. Part 1: the metabolic movers.
    Larter CZ; Chitturi S; Heydet D; Farrell GC
    J Gastroenterol Hepatol; 2010 Apr; 25(4):672-90. PubMed ID: 20492324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fatty liver disease: predictors of nonalcoholic steatohepatitis and gallbladder disease in morbid obesity.
    Liew PL; Lee WJ; Wang W; Lee YC; Chen WY; Fang CL; Huang MT
    Obes Surg; 2008 Jul; 18(7):847-53. PubMed ID: 18459024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.